{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:50:15Z","timestamp":1792709415921,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304422"],"award-info":[{"award-number":["82304422"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20221043"],"award-info":[{"award-number":["BK20221043"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jconrel.2025.01.008","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T17:53:22Z","timestamp":1736531602000},"page":"221-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Hybrid prodrug nanoassembly for hypoxia-triggered immunogenic chemotherapy and immune modulation"],"prefix":"10.1016","volume":"379","author":[{"given":"Beiyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaojie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2025.01.008_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216345","article-title":"Hypoxia induces immunosuppression, metastasis and drug resistance in pancreatic cancers","volume":"571","author":"Zhang","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.008_bb0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.jconrel.2025.01.008_bb0015","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.jconrel.2025.01.008_bb0020","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.ijrobp.2017.03.024","article-title":"Clinical advances of hypoxia-activated prodrugs in combination with radiation therapy","volume":"98","author":"Mistry","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"10","key":"10.1016\/j.jconrel.2025.01.008_bb0025","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/bjc.2016.79","article-title":"Hypoxia-activated prodrugs: paths forward in the era of personalised medicine","volume":"114","author":"Hunter","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.01.008_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100787","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"59","author":"Kopecka","year":"2021","journal-title":"Drug Resist. Updat."},{"issue":"3","key":"10.1016\/j.jconrel.2025.01.008_bb0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drup.2011.03.001","article-title":"Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways","volume":"14","author":"Rohwer","year":"2011","journal-title":"Drug Resist. Updat."},{"issue":"3","key":"10.1016\/j.jconrel.2025.01.008_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22039","article-title":"Interleukin-6 contributes to chemoresistance in MDA-MB-231 cells via targeting HIF-1\u03b1","volume":"32","author":"Wang","year":"2018","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.008_bb0045","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1038\/s41467-021-26407-4","article-title":"Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy","volume":"12","author":"Bent","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2025.01.008_bb0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","article-title":"Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells","volume":"26","author":"Lee","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.008_bb0055","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-018-0618-0","article-title":"miR-519a enhances chemosensitivity and promotes autophagy in glioblastoma by targeting STAT3\/Bcl2 signaling pathway","volume":"11","author":"Li","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2025.01.008_bb0060","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.drudis.2020.11.032","article-title":"Role of STAT3 signaling transduction pathways in cancer stem cell-associated chemoresistance","volume":"26","author":"Shih","year":"2021","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.jconrel.2025.01.008_bb0065","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.canlet.2011.10.011","article-title":"Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells","volume":"315","author":"Huang","year":"2012","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.008_bb0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nri1995","article-title":"Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment","volume":"7","author":"Yu","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.008_bb0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nm976","article-title":"Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells","volume":"10","author":"Wang","year":"2004","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.jconrel.2025.01.008_bb0080","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1158\/0008-5472.CAN-12-4563","article-title":"BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages","volume":"73","author":"Lee","year":"2013","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.jconrel.2025.01.008_bb0085","article-title":"STAT3 signaling in breast cancer: multicellular actions and therapeutic potential","volume":"14","author":"S.Q. To","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.jconrel.2025.01.008_bb0090","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2326-6066.CIR-14-0075","article-title":"Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists","volume":"2","author":"Sitkovsky","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"35","key":"10.1016\/j.jconrel.2025.01.008_bb0095","doi-asserted-by":"crossref","first-page":"13132","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"277","key":"10.1016\/j.jconrel.2025.01.008_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa1260","article-title":"Immunological mechanisms of the antitumor effects of supplemental oxygenation","volume":"7","author":"Hatfield","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2025.01.008_bb0105","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-134336","article-title":"Biomarker-driven phase Ib clinical trial of OPB-111077 in acute myeloid leukemia increases overall response rates","volume":"136","author":"Martinez-Lopez","year":"2020","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.jconrel.2025.01.008_bb0110","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/hepr.12504","article-title":"Phase 1 and pharmacological trial of OPB-31121, a signal transducer and activator of transcription-3 inhibitor, in patients with advanced hepatocellular carcinoma","volume":"45","author":"Okusaka","year":"2015","journal-title":"Hepatol. Res."},{"issue":"10","key":"10.1016\/j.jconrel.2025.01.008_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055718","volume":"12","author":"Nishina","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jconrel.2025.01.008_bb0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0959-8049(14)70343-0","article-title":"217 results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced\/metastatic hepatocellular carcinoma","volume":"50","author":"Kang","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jconrel.2025.01.008_bb0125","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jconrel.2022.10.050","article-title":"Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics","volume":"352","author":"Ramasamy","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.008_bb0130","article-title":"Bioresponsive nanocomplex integrating cancer-associated fibroblast deactivation and immunogenic chemotherapy for rebuilding immune-excluded tumors","volume":"58","author":"Liu","year":"2024","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2025.01.008_bb0135","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jconrel.2023.07.061","article-title":"Enhancing chemotherapy for pancreatic cancer through efficient and sustained tumor microenvironment remodeling with a fibroblast-targeted nanosystem","volume":"361","author":"Zhou","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.008_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120955","article-title":"Recent trends in bioresponsive linker technologies of prodrug-based self-assembling nanomaterials","volume":"275","author":"Nguyen","year":"2021","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.jconrel.2025.01.008_bb0145","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1016\/j.apsb.2022.08.013","article-title":"Smart drug delivery systems for precise cancer therapy","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"22","key":"10.1016\/j.jconrel.2025.01.008_bb0150","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1039\/D2PY00414C","article-title":"Recent advances in self-immolative linkers and their applications in polymeric reporting systems","volume":"13","author":"Gavriel","year":"2022","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2025.01.008_bb0155","first-page":"273","article-title":"Nano-engineered lymphocytes for alleviating suppressive tumor immune microenvironment, applied","volume":"16","author":"Liu","year":"2019","journal-title":"Mater. Today"},{"key":"10.1016\/j.jconrel.2025.01.008_bb0160","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jconrel.2021.06.034","article-title":"Nanoplatform-based natural products co-delivery system to surmount cancer multidrug-resistant","volume":"336","author":"Liang","year":"2021","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2025.01.008_bb0165","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4155\/fmc-2018-0511","article-title":"NBGNU: a hypoxia-activated tripartite combi-nitrosourea prodrug overcoming AGT-mediated chemoresistance","volume":"11","author":"Ge","year":"2019","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jconrel.2025.01.008_bb0170","first-page":"490","article-title":"ROS-responsive and triple-synergistic mitochondria-targeted polymer micelles for efficient induction of ICD in tumor therapeutics","volume":"36","author":"Hu","year":"2024","journal-title":"Bioact. Mater."},{"issue":"6","key":"10.1016\/j.jconrel.2025.01.008_bb0175","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1021\/acs.bioconjchem.3c00174","article-title":"PEGylated lipid nanoparticle formulations: immunological safety and efficiency perspective","volume":"34","author":"Tenchov","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2025.01.008_bb0180","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.actbio.2023.04.027","article-title":"Hydroxyapatite nanoparticles promote TLR4 agonist-mediated anti-tumor immunity through synergically enhanced macrophage polarization","volume":"164","author":"Wang","year":"2023","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.008_bb0185","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/2159-8290.CD-19-1280","article-title":"Lessons from the A2A adenosine receptor antagonist-enabled tumor regression and survival in patients with treatment-refractory renal cell Cancer","volume":"10","author":"Sitkovsky","year":"2020","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.008_bb0190","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.jconrel.2025.01.008_bb0195","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.tips.2014.09.008","article-title":"Prodrug-based nanoparticulate drug delivery strategies for cancer therapy","volume":"35","author":"Luo","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2025.01.008_bb0200","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jconrel.2022.06.004","article-title":"Taxanes prodrug-based nanomedicines for cancer therapy","volume":"348","author":"Sun","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2025.01.008_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112274","article-title":"Hypoxia-activated nanomedicines for effective cancer therapy","volume":"195","author":"Zhou","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.jconrel.2025.01.008_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115703","article-title":"Cancer cell metabolism in hypoxia: role of HIF-1 as key regulator and therapeutic target","volume":"22","author":"Infantino","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2025.01.008_bb0215","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13046-020-01820-7","article-title":"Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy","volume":"40","author":"Wang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925000100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T12:23:08Z","timestamp":1762258988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925000100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":43,"alternative-id":["S0168365925000100"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.008","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hybrid prodrug nanoassembly for hypoxia-triggered immunogenic chemotherapy and immune modulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}